靶向结合骨肉瘤血管内皮细胞短肽的体外功能验证  

In-vitro Functional Identification of Short Peptide Binding Specifically to Osteosarcoma-associated Vascular Endothelial Cells

作　　者：杨澜波 邹春雨[1] 米豫飞[1] 王战朝[1] 史占军[2] 黄涛[3] Yang Lanbo;Zou Chunyu;Mi Yufei(Luoyang Orthopedic-Traumatological Hospital of Henan Province,Henan 471002,China)

机构地区：[1]河南省洛阳正骨医院、河南省骨科医院,471002 [2]南方医科大学南方医院关节骨病外科,广州510515 [3]中国人民解放军联勤保障部队第989医院,洛阳471031

出　　处：《医学研究杂志》2020年第5期109-112,144,共5页Journal of Medical Research

基　　金：河南省医学科技攻关计划(201404055)。

摘　　要：目的验证体外培养的鼠源性骨肉瘤血管内皮细胞(osteosarcoma-associated vascular endothelial cells,OAVECs)与7肽TKPDKGY(TY-7)的结合特异性。方法原代培养获得OAVECs和裸鼠主动脉血管内皮细胞(aortic endothelial cells,AECs)并进行内皮细胞免疫组化鉴定。合成TY-7并在其N端标记一个荧光素(FITC),通过荧光显微镜和流式细胞仪来评价TY-7与OAVECs、AECs及骨肉瘤细胞UMR-106的亲和度。结果荧光显微镜可见OAVECs与TY-7结合后在镜下清晰显像,而UMR-106细胞和AECs并不显像。流式细胞仪则定量显示TY-7与靶细胞OAVECs的结合率(89.54%)远高于UMR-106(0.27%)和AECs(0.22%)。结论TY-7可高度特异结合OAVECs,而不与AECs及骨肉瘤细胞UMR-106结合。Objective To identify the in-vitro binding specification of the short peptide(TKPDKGY,TY-7)to osteosarcoma-associated vascular endothelial cells.Methods OAVECs and AECs were derived from primary culture and characterized by immunocytochemical technology.TY-7 was synthesized and marked with fluorescein isothiocyanate(FITC).Fluorescence microscopy and flow cytometry were used to detect the in-vitro binding activity.Results Fluorescence microscopy observed that TY-7 was only selectively binding to OAVECs,whereas negligible binding to AECs and UMR-106.Flow cytometry showed that the fluorescence positive cell rate was 89.54%in the OAVECs,0.27%in the UMR-106 and 0.22%in the AECs respectively.Conclusion TY-7 has the specifically binding activity to OAVECs.

关 键 词：骨肉瘤 肿瘤血管内皮细胞 特异性结合肽 体外验证 

分 类 号：R738.1[医药卫生—肿瘤]